Drug Metabolism News and Research

RSS

Speedy drug metabolism more likely to cause multidrug-resistant TB

A UT Southwestern Medical Center study using a sophisticated "glass mouse" research model has found that multidrug-resistant tuberculosis (TB) is more likely caused in patients by speedy drug metabolism rather than inconsistent doses, as is widely believed.

29 Dec 2011

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Comprehensive ADMESeq Research Screening Panel launched

RainDance Technologies, Inc., the Digital Biology Company, and Ambry Genetics, today announced the launch of a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The ADMESeq Research Screening Panel enables researchers to simultaneously interrogate 242 known pharmacogenetic genes using next-generation sequencing (NGS) systems.

24 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

Affymetrix launches Axiom Pan-African Array

Affymetrix, Inc. today announced at the ICHG/ASHG annual conference in Montreal, the worldwide launch of the Axiom Genome-Wide Pan-African Array, the first commercial product to maximize genomic coverage of both common and rare alleles in populations of African ancestry, including West African, East African, and African American.

13 Oct 2011

Sequenom launches iPLEX ADME PGx panel to genotype polymorphisms

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced the launch of its iPLEX ADME PGx panel developed to genotype polymorphisms in genes associated with drug absorption, distribution, metabolism, and excretion (ADME).

4 Oct 2011

Potential new treatment for fragile X syndrome

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

16 Sep 2011

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

UCSF, Kaiser Permanente achieve first major milestone in genomics project

One of the nation's largest and most diverse genomics projects has reached its first major milestone in just 15 months. Scientists have genotyped the DNA and analyzed the length of chromosome tips in more than 100,000 Kaiser Permanente members who agreed to be part of the research.

22 Jul 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

Agilent Technologies introduces mass spectrometry systems at ASMS 2011

Agilent Technologies Inc. today introduced mass spectrometry systems raising performance standards for biology and analytical chemistry analyses at the annual conference of the American Society of Mass Spectrometry.

7 Jun 2011

Thermo Fisher Scientific unveils three new mass spectrometry products at 59th Annual ASMS Conference

Thermo Fisher Scientific Inc., the world leader in serving science, introduced three breakthrough instruments that take mass spectrometry (MS) analysis to new levels of performance in resolution, speed, sensitivity and accuracy. The new instruments were unveiled at the 59th Annual ASMS Conference on Mass Spectrometry and Allied Topics, being held June 5-9 at the Colorado Convention Center.

From Thermo Fisher Scientific Inc. 7 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

2 Jun 2011

Pediatric pain experts discuss safety, efficacy of pain medications in children

Can we be certain that pain medications considered safe for adults, based on extensive clinical data and experience, are equally safe for use in young children? Pediatric pain experts discussed this question today in a panel session at the American Pain Society, www.ampainsoc.org, annual scientific meeting and agreed more short term and long-term clinical data are needed to provide assurances about the safety and efficacy of several pain medications in children.

21 May 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

7 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..

31 Mar 2011

Researchers identify enzyme biomarker that can diagnose early colon cancer

A research team at the University of Colorado Cancer Center has identified an enzyme that could be used to diagnose colon cancer earlier. It is possible that this enzyme also could be a key to stopping the cancer.

28 Mar 2011